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1. Summary
Certain disulfide bonds present in leucocyte membrane proteins are labile and
can be reduced in inflammation. This can cause structural changes that result in
downstream functional effects, for example, in integrin activation. Recent
studies have shown that a wide range of membrane proteins have labile disul-
fide bonds including CD132, the common gamma chain of the receptors for
several cytokines including interleukin-2 and interleukin-4 (IL-2 and IL-4).
The Cys
183–Cys
232 disulfide bond in mouse CD132 is susceptible to reduction
by enzymes such as thioredoxin (TRX), gamma interferon-inducible lysosomal
thiolreductase and protein disulfide isomerase, which are commonly secreted
during immune activation. The Cys
183–Cys
232 disulfide bond is also reduced
in an in vivo lipopolysaccharide (LPS)-induced acute model of inflammation.
Conditions that lead to the reduction of the Cys
183–Cys
232 disulfide bond in
CD132 inhibit proliferation of an IL-2-dependent T cell clone and concomitant
inhibition of the STAT-5 signalling pathway. The same reducing conditions had
no effect on the proliferation of an IL-2-independent T cell clone, nor did they
reduce disulfide bonds in IL-2 itself. We postulate that reduction of the Cys
183–
Cys
232 disulfide in CD132 inhibits IL-2 binding to the receptor complex.
Published data show that the Cys
183–Cys
232 disulfide bond is exposed at the
surface of CD132 and in close contact with IL-2 and IL-4 in their respective
receptor complexes. In addition, mutants in these Cys residues in human
CD132 lead to immunodeficiency and loss of IL-2 binding. These results have
wider implications for the regulation of cytokine receptors in general, as their
activity can be modulated by a ‘redox regulator’ mechanism caused by the
changes in the redox environment that occur during inflammation and acti-
vation of the immune system.
2. Introduction
Disulfide bonds are important in maintaining the structure of extracellular
and secreted proteins, but it is now apparent that some disulfide bonds are
labile and their reduction leads to functional changes [1,2]. The uptake of
some viruses such as HIV [3], Newcastle disease virus [4] and hepatitis C
virus [5] is redox-dependent. Platelet activation is associated with redox-
induced changes at the cell surface [6,7]. Disulfide bonds in the b2 integrins
and aIIbb3 integrin maintain their low affinity state, and thrombus formation
is controlled by the redox state of disulfide bonds in the beta chain of aIIbb3
& 2012 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, provided the original
author and source are credited.[8,9]. The affinity of integrins on other cell types can also be
modulated by reducing agents [10]. For example, the a4
chain integrin a4b1 was shown to have free sulfydryl
groups on treatment of cells with reducing agents [10,11].
The powerful anti-microbial activity of human b-defensin-1
is revealed after reduction of disulfide bonds [12]. IL-4
has been shown to contain a disulfide bond susceptible to
mild reduction [13]. Some ligands for cell surface receptors
are also redox sensitive (e.g. MICA) [14]. Immunization
increases the number of free thiols in lymph nodes [15].
Activation of T cells by dendritic cells leads to secretion of
thioredoxin (TRX) into the extracellular space [16], where it
can catalyse reduction of disulfide bonds on the surface
of cells with which it comes into contact. This activation and
TRX secretion can be limited by the addition of regulatory T
cells [17,18]. In a model of arthritis, disease susceptibility was
shown to correlate with the level of free thiols at the surface of
T cells, and this was dependent on intracellular reactive
oxygen levels [19], suggesting a role for redox chemistry in
autoimmunity. Combined, these data suggest a central role
for redox chemistry at the cell surface in controlling the
levels of the immune response to antigen.
We have recently developed a proteomics-based tech-
nique to determine the membrane proteins of leucocytes
that have labile disulfides using mild reducing conditions
such as dilute tris(2-carboxyethyl)phosphine (TCEP), and
enzymes such as TRX, gamma interferon-inducible lysosomal
thiolreductase (GILT) and protein disulfide isomerase (PDI)
that are commonly secreted during immune activation
[20,21]. After reduction, the proteins with labile disulfide
bonds were labelled with maleimide-PEO2-biotin (MPB).
This enabled these proteins to be purified by avidin affinity
chromatography and, following digestion with trypsin, to
be identified by mass spectrometry. Leucocyte membrane
proteins with labile disulfide bonds were surprisin-
gly common and included various classes of proteins such
as integrins, transporters and adhesion proteins, suggesting
the activity of many proteins may be modulated by redox
changes during immune responses [20]. One protein
identified in these screens was CD132, which is the com-
mon signalling component (gc) of the receptors for several
cytokines, namely IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21
[22]. IL-2 plays a central role in T cell activation and
regulation[23–25],andwenow showthat reductionofthisdis-
ulfide in the CD132 chain of its receptor has a marked effect on
IL-2 signalling. This suggests that responsiveness to IL-2 (and
possibly other cytokines) may be modulated by changes in
the redox environment that occur during immune responses.
3. Results
3.1. Identification of a labile disulfide in CD132
The CD132 chain was identified as containing a redox-labile
disulfide bond (Cys
183–Cys
232) in screens of T cells treated
with the chemical reductant TCEP and three enzymatic
reductants (TRX, GILT and PDI), and also in spleen cells
from mice treated with LPS in a short-term model of inflam-
mation [20]. The peptides identified by mass spectrometry
are summarized in table 1. The three enzymatic reductants
gave similar peptide coverage, which was higher than seen
by TCEP reduction, an observation seen for other proteins
in the global screen [20]. One Cys residue in CD132 was
identified as an MPB-labelled peptide with the sequence
C*LQYLVQYR (table 1; the asterisk indicates the modified
Cys residue), the MS/MS spectrum for this peptide obtained
after PDI reduction (similar spectra were obtained for the
other reducing agents) is shown in figure 1a. This indicates
that this Cys (residue 183) originated from a disulfide bond
that was reduced by the mild reducing conditions described
above and previously [20]. A peptide containing Cys
232,
the other residue that makes up this disulfide bond, was
not detected with an MPB label. However, it was detected
in an unmodified carboimidomethyl form. The protein
sequence of mCD132 and identified peptides are shown in
figure 1b. The MPB label reduces the ionization efficiency of
the peptide compared with unlabelled carboimidomethyl
Cys (C. Metcalfe 2011, unpublished data) containing pep-
tides, thus it is possible that the Cys
232-containing peptide
was undetectable under the conditions employed in the
study. Under TRX- and GILT-reducing conditions, the
C*LQYLVQYR peptide was detected with both MPB and car-
bamidomethyl modifications, indicating that modification of
both Cys residues of the labile disulfide bond was not 100
per cent efficient. In the in vivo, LPS inflammation model
CD132 was detected although no MPB modified peptide
was detected in CD132 or indeed any other protein [20].
This is due to the complexity of the sample. Peptides orig-
inate from proteins of many different cell types and
therefore will be present at levels at the limit of detection of
our mass spectrometry system. Only a small percentage of
these peptides will be labelled with MPB and are therefore
unlikely to be identified on probability grounds.
3.2. The labile disulfide bond in CD132 is exposed
to solvent
The structure of the CD132 ectodomain has been determined
in complexes of both the human IL-2 and IL-4 receptors with
IL-2 and IL-4, respectively (reviewed by LaPorte et al. [26]).
CD132 contains two fibronectin type III domains. The pep-
tide containing the MBP modified Cys identified in mouse
CD132 (see above) corresponds to Cys
160 that forms a disul-
fide bond with Cys
209 in these structures for human
CD132 (figure 2). This domain type has a fold similar to an
Ig-like domain consisting of two beta sheets but it usually
lacks disulfide bonds in the typical Ig inter-sheet position.
However, in some cases disulfide bonds are present, such
as the Cys
160–Cys
209 disulfide of CD132. This disulfide
bond is unusual in that it is at the surface of the protein
(figure 2a) with a large solvent accessibility area of 56 A ˚ 2
(compared with a structure average of 19 A ˚ 2) when calculated
in the absence of IL-2, which is presumably the state under
which redox regulation would occur. This Cys
160–Cys
209
disulfide bond is relatively short, with a Ca–Ca of 5.3 A ˚
compared with an average of 5.9 A ˚ for the other disulfide
bonds present in the IL-2 and IL-4 receptor structures.
These features are compatible with the possibility that this
disulfide bond might be readily reduced. A recent bio-
informatics study that analysed all of the disulfide bonds
in the protein data bank based on solvent accessibility,
Ca–Ca distance and an estimation of torsion strain on the
S–S bonds [1,2] concluded that the most common configur-
ation of the known allosteric disulfide bonds is the
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2–RHStaple. A feature of –RHStaple bonds is the close proxi-
mity of the a-carbon atoms of the two cysteine residues
[27,28]. In both of these structures, the Cys
160–Cys
209 disul-
fide bond sits at the interface of CD132, linking two beta
loops as shown in figure 2c with the cytokine in direct contact
with the helix bundle. The possibility that mild reducing con-
ditions typical of those found in T cell activation might
reduce this disulfide bond enough to affect the ability of IL-
2 to bind and signal through the receptor was investigated.
3.3. Reducing agents inhibit the proliferation of an
IL-2-dependent cell line
Some T cell lines are dependent on IL-2 for growth and are
widely used as bioassays for IL-2. From the above, we predict
that the growth of such a line would be inhibited by mild
reducing conditions by affecting the ability of CD132 to
signal in response to IL-2. One commonly used line is the T
helper clone HT-2 cell line that had been derived from
mouse Balb/c spleen cells stimulated with sheep erythrocytes
and grown in IL-2 [29]. This line was treated with TCEP and
its effects on proliferation were determined by incorporation
of
3H-thymidine. Proliferation was inhibited in a dose-
dependent manner at concentrations of TCEP comparable
to those used to reduce the labile disulfide bond in
CD132 (figure 3a). Washing the TCEP from the cells gave
recovery of proliferation to approximately 80 per cent of con-
trol levels indicating that inhibition was reversible on a
timescale of hours and TCEP caused no significant perma-
nent toxicity to the cell line. In contrast, the same reducing
Table 1. Summary of CD132 reduction data from TCEP, PDI, TRX and GILT reductase extracted from global screens of a 2B4 T cell clone. Data show the
percentage coverage of CD132, the CD132 peptides identiﬁed and any modiﬁcations indicated with their positions within the identifed peptide. Cys denotes the
residue number of the cysteines in the immature mouse CD132. Cys
183 forms a disulﬁde with Cys
232 and the equivalent in the human protein structure is
Cys
160–Cys
209, and the latter nomenclature is used in the discussion. CD132 was also detected in spleen cells following LPS induction of inﬂammation.
reducing agent percentage coverage peptides modiﬁcations Cys
TCEP 2.0 CLQYLVQYR MPB@1 183
PDI 30.9 FSLPSVDELKR
LNLQNLVIPR
NLEDLVTEYQGNFSAWSGVS
SWTELIVNHEPR
YNPICGSSQQWSK carbamidomethyl@5 232
CLQYLVQYR MPB@1 183
GLTESLQPDYSER
MPPIPPIK
VSDNNTFQECSHYLFSK carbamidomethyl@10 102
thioredoxin 31.4 FSLPSVDELKR
GLTESLQPDYSER
LNLQNLVIPR
NLEDLVTEYQGNFSAWSGVSK
SWTELIVNHEPR
YNPICGSSQQWSK carbamidomethyl@5 232
CLQYLVQYR MPB@1 183
CLQYLVQYR carbamidomethyl@1 183
EITSGCQIQK carbamidomethyl@6 115
VSDNNTFQECSHYLFSK carbamidomethyl@10 102
GILT 26.8 FSLPSVDELKR
GLTESLQPDYSER
LNLQNLVIPR
NLEDLVTEYQGNFSAWSGVSK
SWTELIVNHEPR
CLQYLVQYR MPB@1 183
CLQYLVQYR carbamidomethyl@1 183
YNPICGSSQQWSK carbamidomethyl@5 232
EITSGCQIQK carbamidomethyl@6 115
LPS 6.8 SWTELIVNHEPR
GLTESLQPDYSER
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3conditions had no effect on the proliferation of the 2B4 hybri-
doma T cell line that is not dependent on exogenous IL-2 for
proliferation, but still expresses CD132 (figure 3b).
In order to mimic physiological conditions more closely
than TCEP, the effects of TRX were tested. TRX is an
enzyme that reduces disulfide bonds to the free sulfy-
dryls and is known to be produced by dendritic cells and
required for T cell activation [16]. TRX (in the presence of
trace levels of 5 mM dithiothreitol, DTT, as an electron
donor) gave similar inhibition of the HT-2 cells as TCEP
(figure 3c). The TRX had no effect on proliferation of the
2B4 cell line. These results are consistent with previous data
showing mutation of this disulfide bond in CD132 inhibits
IL-2 binding and signalling [30]. In combination, these results
show the Cys
160–Cys
209 disulfide bond is redox-labile and
that CD132-dependent cytokine binding can be affected by
changes in redox potential at the cell surface.
3.4. The disulfide bond in IL-2 is resistant to
mild reduction
Reduction of the cytokine IL-4 by exogenous reducing agents
has been shown to inhibit its ability to bind to the IL-4 recep-
tor complex and inhibits proliferation of an IL-4-dependent
cell line [13]. A similar reduction of IL-2 could account for,
or at least contribute to, the effects seen on the HT-2 cell
line. To test this, recombinant rat IL-2 was incubated under
the same reducing conditions known to give extensive inhi-
bition of HT-2 cell proliferation. N-ethylmaleimide (NEM)
was added to modify any free sulfydryl residues generated.
The IL-2 protein was denatured with urea, fully reduced
with TCEP and alkylated with iodoacetamide (IAA). The
protein was digested with trypsin and peptides analysed by
mass spectrometry. The Cys-containing peptides were ana-
lysed for differential labelling with the two thiol-reactive
agents using a simple semi-quantitative analysis based on
the total ion counts of the peptides’ precursor scan peaks.
This showed that for the FECQFDDEPATVVEFLR peptide
less than 1 per cent contained the NEM-modified Cys com-
pared with the IAA-modified Cys (non-reduced in the native
protein) and for the HLQCLENELGALQR peptide about 28
per cent was in the NEM-modified form (table 2). These data
were almost identical to a control that had not been reduced.
The NEM modification observed was probably due to
some denatured protein in the IL-2 preparation. This indicates
that the disulfide bond in IL-2 was not labile. IL-2 and IL-4
contain one and three disulfide bonds, respectively, and
these disulfide bonds are conserved across several species.
X-ray crystal structures are not available for rat or mouse
IL-2 or IL-4, but human structures are available for both
(figure 4). The tertiary structures of human IL-2 and IL-4 are
very similar (figure 4a), with good overlay of the 4-helix
bundle. Both structures contain a disulfide bond between the
second helix of the bundle and an external loop (figure 4b,c).
IL-4 contains two further disulfide bonds (figure 4b) and IL-
2 contains a conserved ‘free’ cysteine buried inside of the
4-helix bundle (figure 4c). Figure 4d shows the calculated
solvent accessibility for all of the disulfide bonds in IL-2
and IL-4. The Cys
59–Cys
105 disulfide bond in IL-2 is buried,
as are the Cys
24–Cys
65 and Cys
46–Cys
99 disulfide bonds in
IL-4. However, the Cys
3–Cys
127 disulfide bond in IL-4 is
highly solvent exposed and is likely to be the one that
is redox-labile in the previous study [13].
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Figure 1. Analysis of CD132 after reduction with PDI showing peptide coverage and MBP-modified peptide. (a) The MS/MS spectrum of peptide C(MPB)LOYLVQRR
shows good unambiguous coverage of the bþ (red peaks) and yþ (blue peaks) ion series. Sequential individual amino acid masses were identified in both the bþ
and yþ ion series. (b) Amino acid sequence of mouse CD132 showing the peptides identified by mass spectrometry (underlined) and the peptide containing the
biotin-maleimide modification (green; Cys
183 in blue), which forms a labile disulfide bond with the Cys
232 shown in red. Other Cys residues in the structure are
shown in yellow.
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4Pre-reduced and alkylated recombinant rat IL-2 was just
as effective as normal IL-2 in controlling the proliferation of
the HT-2 IL-2-dependent cell line (figure 3d). Therefore,
there is no evidence that the effect of reducing agent on the
IL-2-dependent cell line is due to effects on the IL-2 itself.
3.5. Reduction of CD132 inhibits signalling through the
Jak-3–STAT-5 pathway
Cytokine receptors using CD132 signal through Jak–STAT
pathways. In the case of IL-2 signalling, binding of IL-2 to
the surface receptor complex initiates the recruitment of
Jak-3, which phosphorylates STAT-5, resulting in its
dimerization and translocation to the nucleus to initiate
gene transcription [32]. The level of tyrosine phosphorylation
of STAT-5 is therefore a direct readout for the presence of a
functional IL-2 receptor complex. In order to test the hypoth-
esis that reduction of CD132 inhibits the ability of the IL-2
receptor complex to bind IL-2 and signal through CD132,
we measured levels of tyrosine phosphorylation in STAT-5
(figure 5a; quantitation in figure 5b). IL-2-dependent HT-2
cells were starved of IL-2 for 18 h to give a background
level of STAT-5 tyrosine phosphorylation. The cells were
reduced using identical conditions to those used to identify
the labile disulfide and then either treated with IL-2 for
30 min or first alkylated with NEM and then treated with
IL-2 for 30 min. A third sample of cells was treated with IL-
2 without prior reduction and alkylation. Cells treated with
IL-2 alone resulted in an increased level of tyrosine phos-
phorylation in STAT-5. However, cells treated with IL-2
after reduction or reduction and NEM alkylation showed
STAT-5 tyrosine phosphorylation levels comparable to the
control. This shows that conditions known to reduce the
labile disulfide bond in CD132 directly inhibit cytokine
signalling through the IL-2 receptor complex. Furthermore,
the finding that inhibition occurred with or without NEM
alkylation of the free cysteines shows that this disulfide
does not reform and restore activity once reduced.
To test whether the decrease in STAT-5 tyrosine phos-
phorylation after reduction of CD132 is a pathway-specific
process andthat thereducingagentisnotinhibitingalltyrosine
phosphorylation in the cell, lysates from non-reduced and
reducedHT-2cellswereWesternblottedwithananti-phospho-
tyrosine antibody (figure 5c). This showed there was no
significant decrease in global phosphorylation upon reduction,
and that inhibition of phosphorylation of tyrosines in STAT-5
and cell proliferation is pathway-specific through CD132.
4. Discussion
CD132 was identified as having a labile disulfide bond in
screens to determine the molecular modification of mem-
brane proteins that occurred during inflammation, where it
is known that there are changes in the extracellular redox
environment both in terms of the secretion of enzymes that
can modify disulfide bonds and the overall redox potential
[20]. The specific disulfide in CD132 was identified using a
variety of mild reducing agents including PDI, TRX and
GILT. CD132 was also one of many proteins identified in a
model of inflammation. The detailed structural knowledge
of CD132 in structures of the receptors and their complexes
with IL-2 and IL-4 allows the molecular consequences to be
examined [24,26,33]. The Cys
183–Cys
232 of CD132 that we
identify as labile is solvent exposed in the equivalent struc-
ture for the human proteins at the interface of CD132 and
IL-2 or IL-4. This disulfide bond bridges two loops in
domain 1 of CD132. As described by Wang et al., ‘this disul-
fide bond fixes the bent conformation of loop FG2, where the
main chain atoms from residues Ser-207 to Pro-211 directly
contact the methylene side chain of residue Gln-126 in IL-2
or Arg-121 in IL-4’ (page 48 of [22]). Thus, reduction of this
disulfide probably imparts added flexibility into the loops
affecting IL-2 and IL-4 binding signalling (figure 2). Mutation
of these Cys residues severely disrupts IL-2 binding to
CD132, as shown by cell surface binding of IL-2 to COS-7
CD122  
CD132 cytokine receptor
common g chain   
CD25  
IL-2  
CD132 cytokine receptor 
common g chain  
IL-4 
CD124  
(a)
(b)
(c)
Figure 2. Structures of (a) the human IL-2 receptor complex (PDB accession
2ERJ) and (b) the IL-4 receptor complex (PDB accession 3BPL) in complex
with IL-2 and IL-4, respectively. CD132 is shown in mauve, the cytokine (IL-2
and IL-4) in brown, the beta chain of the receptor in blue. The IL-2 receptor
complex has an additional chain, CD25, shown in green. The Cys
160–Cys
209
disulfide bond identified as being labile in mouse CD132 corresponds to the
same numbered residues in the human structure and is shown as yellow
spheres and lies in contact with the cytokine in both complexes. The other
non-labile disulfide bonds are represented as yellow sticks. (c) Close up of the
Cys
160–Cys
209 disulfide bond (yellow sticks) on CD132 (blue cartoon and
surface) showing that is bridging two loops that are in direct contact with IL-
2 (red cartoon and surface).
r
s
o
b
.
r
o
y
a
l
s
o
c
i
e
t
y
p
u
b
l
i
s
h
i
n
g
.
o
r
g
O
p
e
n
B
i
o
l
2
:
1
1
0
0
3
6
5cells transfected with CD132 mutants, and surface plasmon
resonance analysis on recombinant IL-2 and receptor chains
[30,34]. Mutations in several residues at the CD132–cytokine
interface, including this Cys
160–Cys
209 pair, lead to X-linked
severe combined immunodeficiency syndrome (X-SCID)
[24,35,36]. Our functional data show that mild reduction
inhibits proliferation of an IL-2-dependent T cell clone and
the STAT-5 pathway. This complements analysis showing
that mutation of either of the Cys residues involved in this
disulfide bond inhibits IL-2 binding to its receptor.
CD132 is part of the receptor for several other cytokines
(IL-4, IL-21, IL-7, IL-9, IL-15) [32]. There are clear data for
the IL-4 receptor showing that the labile disulfide in
CD132 is at the interface with the cytokine, and it seems
likely that the other cytokines bind in a similar way [22],
with data indicating at least some overlap between the sites
on CD132 for IL-4 and IL-21 [37]. For IL-4, there is the
added complication that IL-4 itself has a labile disulfide-
affecting function [13]. Thus, the activity of several cytokine
receptors may be affected by a ‘redox regulator’ resulting
from changes in the redox potential and the availability of
thiol-modifying enzymes such as PDI.
The changes in the redox environment are presumably
transient. What happens when conditions return to normal?
The effect of reduction of the receptor is reversible over
a period of hours; this could either be due to the reduced
disulfide bonds reforming after reducing conditions have
been removed, or the cells could be turning over the receptor
at the cell surface and replacing reduced CD132 with newly
synthesized non-reduced CD132. The finding that little spon-
taneous reforming of active CD132 occurred over 30 min
suggests little reformation of the disulfide bond and that
receptor turnover is the primary cause of restoration of
IL-2-dependent cell proliferation. Presumably, the Cys
183–
Cys
232 disulfide bond is formed during biosynthesis in the
presence of chaperones and restrains the loops.
As CD132 is common to a number of cytokine receptors,
there may be a previously undiscovered mechanism control-
ling the levels of responses of cells to exogenous cytokines.
These changes may also occur in other cytokine receptors.
From these data, we would predict that disulfides that are
solvent-exposed and at the interface with the cytokine may
be affected by redox changes with functional effects. Exposed
disulfide bonds are not common in other cytokine receptors
control
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Figure 3. Mild reducing conditions cause inhibition of proliferation of an IL-2-dependent cell line HT-2. (a) Mild reduction with TCEP gives inhibition of proliferation
of HT-2 cells determined by
3H-thymidine incorporation (normalized to 100% for no treatment). The effect is largely reversible as washing restores proliferation
levels. Dark grey bars, HT-2 non-washed; light grey bars, HT-2 washed. (b) Similar reducing conditions give no inhibition of proliferation of the 2B4 T cell hybridoma
(IL-2-independent) compared with the unwashed sample in (a). Dark grey bars, HT-2; light grey bars, 2B4. (c) The reducing enzyme thioredoxin (TRX) causes
inhibition of proliferation of HT-2 cells, but not the 2B4 T cell hybridoma (5 mM DTT is present as an electron donor for TRX enzymatic turnover). (d) Treatment of
purified IL-2 with 2.5 mM TCEP gives no significant difference in its ability to permit proliferation of HT-2 cells. Error bars indicate standard deviation from three
independent experiments.
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6where there are structural data; for example, none of the dis-
ulfides in the interleukin-28 receptor subunit alpha (or
interferon-lambda receptor 1; PDB; 3OG6) is exposed. The
tumour necrosis factor (TNF) receptor family members are
characterized by a high content of disulfide bonds, but in
the TNF–TNFR2 structure (PDB; 3ALQ) two Cys residues
are in contact with the ligand (TNF), but their partners are
solvent-inaccessible. However, there are data to show that
TRX 1 can reduce disulfide bonds in the TNF receptor
family member CD30 giving altered cytokine binding [38].
This study showed that other TNF receptor family members
were not modified, pointing to selected cytokine receptors
being affected. Thus, the activity of some cytokines may be
moderated in immune responses by changes in redox poten-
tial modulated by the release of enzymes such as PDI.
Therefore simple quantitation of the expression of a cytokine
receptor may not be fully predictive of its ability to signal.
5. Material and methods
5.1. Labelling of labile disulfide bonds in 2B4
hybridoma cells and spleen cells
The labelling method and identification of proteins by mass
spectrometry is given in detail by Metcalfe et al. [20]. In
brief, 2B4 cells were treated with 2.5 mM Methyl-PEO12-
maleimide (MPM) to block any free Cys residues, washed
and then incubated with the various reducing agents for
30 min at room temperature. The cells were washed and
reacted with 2.5 mM MPB, and left to rotate at 48 for
30 min to biotinylate any free sulfydryls formed in the
reduction step. After washing, the cells were lysed in 1 per
cent Triton X-100 with 5 mM N-ethylmaleimide and mem-
brane glycoproteins purified by lentil lectin affinity
chromatography. The modified proteins were repurified
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Figure 4. The structures of IL-2 and IL-4 are similar, but one disulfide bond in IL-4 is massively exposed to solvent. (a) Superposition of human IL-2 (red) and
human IL-4 (green), derived from structures of the whole IL-2 and IL-4 cytokine receptor complex PDB ID:2ERJ and 3BPL, respectively, showing the similarity of the
structures. (b) Structure of IL-4 alone showing the position of the three disulfide bonds (yellow sticks). (c) Structure of IL-2 alone showing the position of its
disulfide bond (yellow sticks) and free cysteine (yellow). (d) Solvent accesibility of the disulfide bonds in IL-2 (red bars) and IL-4 (blue bars). Calculated using
software [31] and http://www.cancerresearch.unsw.edu.au/CRCWeb.nsf/page/Disulfide+Bond+Analysis.
Table 2. Precursor ion intensities of Cys-containing peptides for trypsin
digest of TCEP-reduced recombinant rat IL-2. Each peptide was observed
multiple times owing to deaminidation. The ﬁgures given are for the sum
of the ion intensities for each set of peptides either non-reduced
(carboimidomethyl modiﬁcation) or reduced (NEM modiﬁcation). Ratios of
precursor ion intensities were used to determine the relative level of
reduction of the disulﬁde bond in IL-2. There are no structures for rat or
mouse IL-2, but the Cys residues in rat IL-2 (78 and 126 indicated after the
modiﬁcation; UNIPROT accession; P17108) correspond to residues 58
and 105 in the X-ray crystal structure of human IL-2 (ﬁgure 2 and PDB
code 2erj).
peptide modiﬁcation
sum of
precursor
ion
intensities
HLQCLENELGALQR carbamidomethyl@4
[78]
13 100 000
HLQCLENELGALQR N-ethylmaleimide@4
[78]
5 200 000
FECQFDDEPATVVEFLR carbamidomethyl@3
[126]
29 600 000
FECQFDDEPATVVEFLR N-ethylmaleimide@3
[126]
184 000
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7using monomeric avidin beads (Pierce Chemical Company,
Rockford, IL) and the eluent was digested with PNGase F
and trypsin. The tryptic peptide samples were desalted on
a C18 packed pipette tip system and injected onto an Ulti-
mate 3000 nano HPLC (Dionex) system coupled with
Orbitrap XL mass spectrometer (Thermo Electron).
LPS-induced inflammation was induced in a mouse as
described [20]. One microgram of LPS (Sigma Chemical Com-
pany, St Louis, MO) in PBS was given intraperitoneally
to each adult Balb/c mouse and the spleen taken after 3 h.
Control mice received PBS alone. The spleen cells were
teased out into RPMI containing 2.5 mM MBP and gently
agitated at 48C for 30 min. The cells were washed and
processed as for the cell lines.
5.2. Data processing
T h ed a t aw e r es u b m i t t e dt ot h ei n - h o u s eC e n t r a lP r o t e o m i c s
Facilities Pipeline (CPFP) [39] and the datasets were searched
withvariablepeptidemodificationsincludingcarbamidomethyl
cysteine, oxidized methionine, deamidated asparagine/
glutamine, and hydrolysed and non-hydrolysed versions of
the appropriate cysteine-modifying label (NEM, MPM or
MPB). The resulting peptide identifications from each search
engine were validated with PEPTIDEPROPHET and PROTEINPROPHET
and lists compiled at the peptide and protein level [40]. IPROPHET
was used to combine the identifications from three search
engines and further refine identifications and probabilities [41].
Normalized spectral index quantitation (SINQ) was applied to
the grouped meta-searches to give protein-level quantitation
between reduced samples and controls [42]. All lists of peptide
and protein identifications were generated with a probability
cut-off corresponding to a 1 per cent false discovery rate (FDR)
relative to a target decoy database. Quantitated datasets were
uploaded to ProteinCenter (Proxion, Thermofisher) for analysis.
The dataset was reduced by removing single-peptide identifi-
cations and proteins of interest (cell surface, secreted and
extracellular) were mined using gene ontology (GO) flags.
Resultant protein and peptide lists were exported as tables.
5.3.
3H-thymidine incorporation by HT-2 cells
HT-2 cells (ATCC; code CRL-1841) were grown in the pres-
ence of IL-2 (approx. 100 U ml
21 of recombinant rat IL-2
produced in house from a Chinese hamster ovary cell
expression system) and then starved of exogenous IL-2 for
18 h. Cells were either reduced with 2.5 mM TCEP or
0.5 mgm l
21 TRX (with 5 mM DTT present) in PBS-containing
1 per cent BSA and, if required, alkylated with 2.5 mM
MPM for 30 min to alkylate any labile disulfides. A total of
TCEP then IL-2
IL-2 
(a)
(b)
–+ – – – + +
TCEP – – + – + + +
MPM – – – + + – +
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Figure 5. Reduction of CD132 inhibits cell proliferation through the STAT-5 pathway. (a) Lysates from HT-2 cells treated with combinations of IL-2, TCEP and MPM
(to block free Cys residues) were probed by Western blot with anti-phospho STAT-5. Levels of STAT-5 were revealed with STAT-5 antibody. (b) Levels of phospho-
STAT-5 were determined by densitometry and the ratio to total STAT-5 calculated. The results are shown as densities relative to IL-2-only treated cells. Data
are representative of three independent experiments. (c) HT-2 cells were treated with reducing conditions as indicated, lysed and probed with the 4G10 anti-
phoshotyrosine antibody. The reducing conditions that affected CD132 signalling did not have a major effect on the overall levels of phosphorylation.
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81.5   10
4 cells per well were incubated for 18 h with
3H-thy-
midine in RPMI containing 10 per cent FCS and 2 per cent
recombinant rat IL-2 supernatant. Cells were harvested onto
filter mats that were saturated in scintillation fluid and radio-
activity measured on a scintillation counter. Twelve identical
wells were counted for each condition and the experiments
were carried out in triplicate.
5.4. Reduction and alkylation of IL-2
Recombinant rat IL-2 (Peprotech, Rocky Hill, NJ) was
reduced for 30 min with 2.5 mM TCEP in PBS at room temp-
erature. Any labile disulfide bonds formed were alkylated
with 2.5 mM NEM in PBS for 30 min. After washing through
a micro concentrator (Millipore, YM-10), the IL-2 was
denatured (8 M urea, 1 h), reduced (10 mM DTT, 378C,
30 min) and alkylated (10 mM IAA, 1 h). The IL-2 was
thoroughly washed with 25 mM ammonium bicarbonate
and then subjected to trypsin digest and mass spectrometry
as described previously.
5.5. Analysis of STAT-5 phosphorylation state
HT-2 cells were grown in the presence of IL-2 and then
starved of exogenous IL-2 for 18 h. A total of 5   10
5 cells
were either reduced (2.5 mM TCEP for 30 min) or reduced
and alkylated (2.5 mM TCEP þ 2.5 mM MPM for 30 min)
and then treated with IL-2 (recombinant rat supernatant)
for 30 min. Control samples (5   10
5 cells) were treated with
IL-2 for 30 min without prior reduction and alkylation.
Cells were then lysed in 1 per cent Triton-X100 in PBS
and subjected to Western blot analysis with rabbit anti-
mouse STAT-5 (3H7, Cell Signaling Technology, Boston,
MA) and rabbit anti-mouse phospho (Y694) STAT-5 (Cell
Signaling Technology). Densitometry quantitation of the
STAT-5 and phosphoSTAT-5 bands was performed using
IMAGEJ (NIH, USA). All experiments were carried out
in triplicate.
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